Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Par Acquires Seroquel ANDA From Handa, Expects First-Filer Exclusivity Upon 2016 Launch

Drug Industry Daily

Oct. 30, 2012 | Vol. 11 No. 213

Par Acquires Seroquel ANDA From Handa, Expects First-Filer Exclusivity Upon 2016 Launch

Par Pharmaceutical can launch a generic version of AstraZeneca’s extend-release antipsychotic Seroquel XR by November 2016 following its acquisition of Handa Pharmaceuticals’ ANDA.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Related Articles

House Committee Probes FDA Official’s Departure Briefs Actavis Buys Warner Chilcott In $8.5B All Stock Purchase Actavis Buys Warner Chilcott for $8.5 Billion

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.